.png){kind=icon}
.png){kind=icon}
Return
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma
.png){kind=icon}
PRE
AI
Y
C
S
M
H
J
O
T
T
A
R
L
J
J
P
P
DOI：10.1080/13543784.2026.2660911.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
In recent years, anti-CD38 antibodies have become integral to the multiple myeloma (MM) treatment armamentarium and greatly improved depth of response and patient outcomes. Isatuximab, an anti-CD38 antibody, is approved for both newly diagnosed MM and relapsed/refractory MM. Understanding the distinct mechanistic features of isatuximab within the anti-CD38 drug class provides further insight into treatment selection.
This review discusses the unique mechanism of action of isatuximab, supporting preclinical data, and differentiation from other anti-CD38 antibodies. It will delve into evidence demonstrating the favorable benefit-risk profile of isatuximab in broad patient populations across the MM treatment continuum.
Isatuximab elicits antitumor activity via multiple tumor-targeting pathways. The direct cytotoxic mechanism of isatuximab is a key differentiator from other anti-CD38 antibodies and translates into clinical benefits in patients with MM. Isatuximab only relies partly on complement-dependent cytotoxicity activity for its antitumor activity, which may have beneficial prognostic implications for patients with 1q21 chromosomal abnormalities and extramedullary disease. This is supported by clinical data, which demonstrate a favorable benefit/risk profile in MM patients including difficult-to-treat patients with poor prognostic outcomes. Further, addition of the novel on-body injector to isatuximab administration modalities may provide advantages over current administration methods.
Keywords:
CD38
direct apoptosis
direct cytotoxicity
isatuximab
multiple myeloma
monoclonal antibody
newly diagnosed
relapsed/refractory
on-body injector
1q21
Journal
E
IF:
4.1
Papers:
3.4K
Citations:
5.7K
Organization
Cited Papers